Fig. 2From: Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancerKaplan-Meier plots of progression-free (a) and overall (b) survivalBack to article page